Mankind Pharma

Mankind Pharma

MANKIND.NSApproved
New Delhi, IndiaFounded 1995mankindpharma.com

Mankind Pharma Limited is one of India's largest pharmaceutical companies by domestic sales, founded in 1991 and headquartered in New Delhi. The company focuses on developing, manufacturing, and marketing branded generic formulations across diverse therapeutic segments. With a strong presence in the Indian pharmaceutical market and growing international footprint, Mankind Pharma went public in 2023 and continues to expand its product portfolio and market reach through strategic acquisitions and partnerships.

Market Cap
$8.8B
Founded
1995
Employees
8,000-12,000
Focus
Biotech

MANKIND.NS · Stock Price

USD 2000.00+577.70 (+40.62%)

Historical price data

AI Company Overview

Mankind Pharma Limited is one of India's largest pharmaceutical companies by domestic sales, founded in 1991 and headquartered in New Delhi. The company focuses on developing, manufacturing, and marketing branded generic formulations across diverse therapeutic segments. With a strong presence in the Indian pharmaceutical market and growing international footprint, Mankind Pharma went public in 2023 and continues to expand its product portfolio and market reach through strategic acquisitions and partnerships.

Technology Platform

Branded generic pharmaceutical manufacturing and development platform with capabilities across multiple dosage forms including oral solids, injectables, and topical formulations.

Pipeline Snapshot

2

2 drugs in pipeline, 1 in Phase 3

DrugIndicationStage
Test - Bimatoprost 0.01% Ophthalmic Solution + Reference - LUMIGAN® (Bimatoprost...Glaucoma, Open-AnglePhase 3
MKP10241 + PlaceboType 2 Diabetes Mellitus (T2DM)Phase 2

Funding History

1
IPOUndisclosedUndisclosedMay 15, 2023

FDA Approved Drugs

1
VARENICLINE TARTRATEANDAAug 1, 2023

Opportunities

Significant growth opportunities in expanding Indian healthcare market, international market penetration in emerging economies, and growing consumer healthcare segment with increasing self-care adoption.

Risk Factors

Key risks include regulatory pricing pressures, intense competition in branded generics market, geographic concentration in India, and potential supply chain disruptions affecting raw material costs.

Competitive Landscape

Competes with major Indian pharma companies like Sun Pharma, Cipla, and Dr. Reddy's, but differentiates through strong domestic branded generics focus, established brand portfolio, and extensive distribution network rather than export-focused generic strategies.

Publications
19
Patents
16
Pipeline
2
FDA Approvals
1

Company Info

TypeTherapeutics
Founded1991
Employees8,000-12,000
LocationNew Delhi, India
StageApproved
RevenueRevenue Generating

Trading

TickerMANKIND.NS
ExchangeNSE

Therapeutic Areas

CardiologyDiabetologyAnti-infectivesGastroenterologyWomen's HealthDermatologyConsumer Healthcare
SIMILAR COMPANIES
Sun Pharmaceutical
Sun Pharmaceutical
Pre-clinical ·
Lupin Limited
Lupin Limited
Pre-clinical ·
Aurobindo Pharma
Aurobindo Pharma
Pre-clinical · Hyderabad
Dr. Reddy's Laboratories
Dr. Reddy's Laboratories
Pre-clinical · Princeton
Abbott India
Abbott India
Pre-clinical · Mumbai
Is this your company?

Claim your profile to update information, add pipeline data, and connect with investors.

Claim profile